A moisturiser study for people with psoriasis
Part of Skin clinical trials.
This study tests whether a moisturiser called Doublebase Once is safe and works well for people with psoriasis. You would use this moisturiser instead of your usual one for about a month to see how your skin reacts and feels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have psoriasis, diagnosed by a healthcare professional.
- You regularly use a leave-on moisturiser/emollient for your skin.
- You are willing to use only the study moisturiser (Doublebase Once) for about one month.
- You are not allergic to any ingredients in the product.
- You are not living in Northern Ireland.
- You can read and complete questionnaires in English.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This study tests whether adding a special moisturizer, Ceramol PSOR cream, to standard narrowband UVB light therapy helps reduce psoriasis symptoms like itching and dryness. It is for people with mild to moderate plaque psoriasis who are already planning to have light therapy.
This study tests a new oral medication for psoriasis in healthy volunteers to check its safety and how the body handles it. It is an early-phase trial to gather information before testing in patients.
This study follows people with psoriasis over time to better understand the condition and how it changes. You may be able to join if your psoriasis started more than 3 years ago and you can agree to take part.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.